drug · small molecule
pemigatinib
Marketedupdated 3mo agoby $INCY INCYTE CORP🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 11 investigational indications.
targets
Fibroblast growth factor receptor 3Fibroblast growth factor receptor 1Fibroblast growth factor receptor 2
all catalysts(0)
nothing on the calendar yet
Trials studying pemigatinib
- phase2Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
- phase2Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
- phase2PH 2 Pemigatinib in SDH-deficient GIST
- phase2A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
- phase2A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
- phase1Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
- phase2Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
- phase1Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 17, 2027
242 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Oct 3, 2040compositionUS 12552792
- Oct 3, 2040compositionUS 12552792
- Oct 3, 2040compositionUS 12552792
- Aug 30, 2040method-of-use (U-3571)US 11628162
- Aug 30, 2040method-of-use (U-3571)US 11628162
- Aug 30, 2040method-of-use (U-3571)US 11628162
- May 3, 2039method-of-use (U-3466)US 11466004
- May 3, 2039method-of-use (U-3466)US 11466004
- May 3, 2039method-of-use (U-3466)US 11466004
- Jan 30, 2035compositionUS 9611267
- Jan 30, 2035compositionUS 9611267
- Jan 30, 2035compositionUS 9611267
- Apr 17, 2034method-of-use (U-2809)US 10131667
- Apr 17, 2034method-of-use (U-2809)US 10131667
- Apr 17, 2034method-of-use (U-2809)US 10131667
FDA exclusivities (6)
- Aug 26, 2029ODE-404Orphan Drug (7y)3.0y
- Aug 26, 2029ODE-404Orphan Drug (7y)3.0y
- Aug 26, 2029ODE-404Orphan Drug (7y)3.0y
- Apr 17, 2027ODE-292Orphan Drug (7y)242d
- Apr 17, 2027ODE-292Orphan Drug (7y)242d
- Apr 17, 2027ODE-292Orphan Drug (7y)242d
News(1)
- Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen optionsIncyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.fiercebiotech · 20d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that